Kolorektale Lebermetastasen: Aktueller Stand der multimodalen Therapie

Surgical resection is the only chance of cure for patients with colorectal liver metastases und significantly improves patient survival. The percentage of patients who can undergo curative resection as well as the survival after liver resection can be increased by using modern multimodal treatment algorithms. This has been achieved by not only innovations in pre- and postoperative chemotherapy but also by new surgical and interventional techniques and last but not least by individualisation of chemotherapeutic regimens. Due to the high number of new treatment modalities, a generally accepted treatment algorithm cannot be provided so far for all subgroups of the inhomogeneous group of patients with colorectal liver metastases. In the present review the current status of multimodal therapy is outlined and the pending questions mentioned.

[1]  J. Fahlke,et al.  Palliative Chemotherapie beim kolorektalen Karzinom – Stand, Wertigkeit, Tendenzen , 2010, Zentralblatt fur Chirurgie.

[2]  P. Colombo,et al.  Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases? , 2010, Annals of surgery.

[3]  F. Lévi,et al.  Regenerative Nodular Hyperplasia of the Liver Related to Chemotherapy: Impact on Outcome of Liver Surgery for Colorectal Metastases , 2010, Annals of Surgical Oncology.

[4]  M. Mottolese,et al.  Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial , 2010, British Journal of Cancer.

[5]  M. Puhan,et al.  Impact of Preoperative Bevacizumab on Complications After Resection of Colorectal Liver Metastases: Case-Matched Control Study , 2010, World Journal of Surgery.

[6]  P. Wust,et al.  Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[7]  S. Curley,et al.  Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases , 2010, Annals of Surgical Oncology.

[8]  P. Bachellier,et al.  Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  S. Curley,et al.  Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? , 2010, Journal of the American College of Surgeons.

[10]  T. Helmberger,et al.  Interventionelle Verfahren bei Lebermetastasen , 2010, Der Chirurg.

[11]  J. Vauthey,et al.  Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  U. Neumann,et al.  The surgical treatment of hepatic metastases in colorectal carcinoma. , 2010, Deutsches Arzteblatt international.

[13]  S. Curley,et al.  Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. , 2010, Archives of surgery.

[14]  E. Abdalla,et al.  Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin‐associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis , 2010, Histopathology.

[15]  D. Seehofer,et al.  The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[16]  R. J. Haas,et al.  Impact of portal vein embolization on long‐term survival of patients with primarily unresectable colorectal liver metastases , 2010, The British journal of surgery.

[17]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[18]  C. Bokemeyer,et al.  A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  V. Georgoulias,et al.  Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  O. Drognitz,et al.  Zeitlicher Ablauf von Leber- und Darmresektion bei Patienten mit kolorektalem Karzinom und synchronen Lebermetastasen , 2009 .

[21]  D. Sargent,et al.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Schwartz,et al.  Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Mocellin,et al.  Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. , 2009, The Cochrane database of systematic reviews.

[24]  U. Neumann,et al.  Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. , 2009, Surgery.

[25]  M. Ychou,et al.  Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  T. Gruenberger,et al.  Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  V. Paradis,et al.  Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab , 2009, Annals of Surgical Oncology.

[28]  B. Nordlinger,et al.  Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. , 2009, Surgery.

[29]  E. Vasile,et al.  Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases , 2009, Annals of surgery.

[30]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Bismuth,et al.  Long-Term Results of Two-Stage Hepatectomy for Irresectable Colorectal Cancer Liver Metastases , 2008, Annals of surgery.

[32]  R. Labianca,et al.  Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Adam,et al.  R1 Resection by Necessity for Colorectal Liver Metastases: Is It Still a Contraindication to Surgery? , 2008, Annals of surgery.

[34]  J. Riemann1,et al.  S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008 , 2008 .

[35]  T. Seufferlein,et al.  S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008 , 2008, Zeitschrift fur Gastroenterologie.

[36]  I. B. Borel Rinkes,et al.  RADIOFREQUENCY ABLATION (RFA) COMBINED WITH CHEMOTHERAPY FOR UNRESECTABLE COLORECTAL LIVER METASTASES (CRC LM): INTERIM RESULTS OF A RANDOMISED PHASE II STUDY OF THE EORTC-NCRI CCSG-ALM INTERGROUP 40004 (CLOCC) , 2008 .

[37]  W. Scheithauer,et al.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Thomas Gruenberger,et al.  Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[40]  L. Schwartz,et al.  Combined Portal Vein Embolization and Neoadjuvant Chemotherapy As a Treatment Strategy for Resectable Hepatic Colorectal Metastases , 2008, Annals of surgery.

[41]  C. Sempoux,et al.  Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[42]  M. Ducreux,et al.  Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin , 2007, Annals of Surgical Oncology.

[43]  W. Jochum,et al.  Hepatic Steatosis Is a Risk Factor for Postoperative Complications After Major Hepatectomy: A Matched Case-Control Study , 2007, Annals of surgery.

[44]  R. Parks,et al.  Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. , 2007, Journal of the American College of Surgeons.

[45]  Daniel Azoulay,et al.  Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Catherine Julié,et al.  Complete response of colorectal liver metastases after chemotherapy: does it mean cure? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Morel,et al.  Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary , 2006, The British journal of surgery.

[48]  R. Hutchins,et al.  Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. , 2006, The British journal of radiology.

[49]  T. Pawlik,et al.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  V. Vilgrain,et al.  Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction , 2006, Journal of Gastrointestinal Surgery.

[51]  B. Nordlinger,et al.  Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases , 2006, Annals of surgery.

[52]  C. Köhne,et al.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  M. Pocard,et al.  Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases , 2005, Journal of surgical oncology.

[54]  F. Lévi,et al.  Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.

[55]  P. Bachellier,et al.  A Two-Stage Hepatectomy Procedure Combined With Portal Vein Embolization to Achieve Curative Resection for Initially Unresectable Multiple and Bilobar Colorectal Liver Metastases , 2004, Annals of surgery.

[56]  R. Felix,et al.  Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events. , 2004, Journal of vascular and interventional radiology : JVIR.

[57]  L. Rubbia‐Brandt,et al.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  M. Gonen,et al.  Second Liver Resections Are Safe and Effective Treatment for Recurrent Hepatic Metastases from Colorectal Cancer: A Bi-institutional Analysis , 2002, Annals of surgery.

[59]  T. Muto,et al.  Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization , 2001, Hepatology.

[60]  T. de Baère,et al.  During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma , 1999, The British journal of surgery.

[61]  R. Reznek,et al.  Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. , 1998, British Journal of Cancer.

[62]  A. Altendorf-Hofmann,et al.  Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history , 1990, The British journal of surgery.

[63]  J. Weitz,et al.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.

[64]  R. Parks,et al.  Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer ( EORTC Intergroup trial 40983 ) : a randomised controlled trial , 2008 .

[65]  M. Ducreux,et al.  Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure , 2007, Annals of Surgical Oncology.